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Abstract 
Background: Despite the extensive use of high-flow nasal cannula (HFNC) therapy in intensive care units (ICU) for 
acute respiratory failure (ARF), its daily clinical practice has not been assessed. We designed a regional survey in ICUs 
in North-west France to evaluate ICU physicians’ clinical practice with HFNC.
Materials and methods: We sent an observational survey to ICU physicians from 34 French ICUs over a 6-month 
period in 2016–2017. The survey included questions regarding the indications and expected efficiency of HFNC, prac-
tical aspects of use (initiation, weaning) and satisfaction. Comparisons between junior and senior ICU physicians were 
performed using a Fischer exact test.
Results: Among the 235 ICU physicians contacted, 137 responded (58.3%) all of whom regularly used HFNC. Hypox-
emic ARF was considered a good indication for HFNC by all 137, but only 30% expected HFNC success (i.e., avoid-
ing intubation in at least 60% of cases). Among hypoxemic indications, 30% of juniors considered acute pulmonary 
edema a good indication versus 74% of seniors (p < 0.0001). Hypercapnic ARF was considered a good indication by 
33% with only 2% expecting HFNC success. A need for conventional oxygen therapy ≥ 6 L/min justified HFNC therapy 
for 40% and ≥ 9 L/min for 39% of responders. 58% of ICU physicians started HFNC therapy with a  FiO2 ≥ 50% and 28% 
with a gas flow ≥ 50 L/min. Practices for HFNC weaning were heterogeneous: 48% considered a  FiO2 ≤ 30%; whereas, 
30% considered a  FiO2 ≤ 30% with a high flow ≤ 20 L/min. Criteria for HFNC failure (i.e., need for intubation) were ven-
tilatory pauses or arrest (97%), persistent hypoxemia (95%), respiratory acidosis (81%), worsening of breathing (95%, 
100% of seniors and 86% of juniors, p = 0.003), bronchial congestion (75%) and circulatory failure (61%, 72% of seniors 
and 44% of juniors, p = 0.007).
Conclusion: HFNC is used by ICU physicians in many situations of ARF, despite their relatively low expectations of 
success, especially in cases of hypercapnia. Clinical practices appear somewhat heterogeneous. Despite the physi-
ological benefit of HFNC, further prospective observational studies are still required on HFNC outcomes and daily 
practices.
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Introduction
High-flow nasal cannula (HFNC) is an oxygen support 
device recently developed as an alternative to conven-
tional oxygen therapy (COT). HFNC consists of an air/
oxygen blender connected through an active heated 
humidifier to nasal cannula. It allows adjustment of the 
fraction of inspired oxygen  (FiO2) independent of the 
flow rate and the gas mixture. HFNC is associated with 
several physiological benefits and many studies have 
shown improvement in comfort and outcomes in various 
clinical settings [1]. Indeed, HFNC has been shown to be 
potentially useful and efficient in hypoxemic acute respir-
atory failure (ARF) [2], major post-operative care [3–5], 
immunocompromised patients [6, 7], for preoxygenation 
[8–11] or during bronchoscopy [12, 13]. Despite exten-
sive literature exploring the interest of HFNC in critical 
care settings, very few studies, to our knowledge, have 
evaluated intensive care unit (ICU) physicians’ experi-
ence and their daily practice with HFNC in terms of 
clinical indications and modalities of use, as well as their 
subjective perception and confidence in the device. The 
objective of this study was, therefore, to evaluate ICU 
physicians’ daily clinical practice of the use of HFNC in 
ICUs in North-west France, as well as their perception of 
the usefulness of the device in various clinical settings.
Materials and methods
Study design
We conducted a prospective declarative survey during 
a 6-month period between October 2016 and March 
2017. ICU physicians’ from The BoReal ICU study group 
(a clinical research network including 34 ICUs in North 
west France, 7 from University Hospital and 27 from 
General non University Hospital), were surveyed through 
a questionnaire sent electronically via the online software 
 SurveyMonkey® (https ://fr.surve ymonk ey.com), devel-
oped according to available guidelines [14]. Briefly, the 
survey was designed by two ICU physicians (one senior 
and one junior) and then tested by five experienced ICU 
physicians before being sent to the whole population of 
interest. It was first sent in October 2016. Non-respond-
ers were contacted a second time in March 2017. One 
month later, ICU physicians who had not completed the 
survey were definitively categorized as non-responders. 
The survey was anonymous and responders were able to 
skip some questions at their discretion.
Description of the survey
The complete survey is available in the Additional file 1. 
The first part of the survey was intended for the ICU 
Medical Head and included questions regarding demo-
graphic data and activity of the ICU during the year 
2015 (number of ICU physicians, seniority, number of 
beds, number of admissions, use of mechanical ventila-
tion). The second part was intended for all physicians 
of the ICU and divided into several sections: (1) usual 
indications of HFNC according to the ICU physician; 
(2) expected success of HFNC according to the ICU 
physician i.e. avoiding the need for intubation; (3) daily 
management of HFNC: criteria for initiation, initial 
parameters of use, modalities of use and HFNC wean-
ing; (4) criteria of HFNC failure (need for intubation); 
and (5) global satisfaction. A psychometric Likert scale 
was used to assess the ICU physician’s perception for 
the different possible HFNC indications. Four proposals 
were suggested: “do not agree at all”, “rather do not agree”, 
“rather agree”, “totally agree”. The indication was clas-
sified as relevant if the ICU physician answered “rather 
agree” or “totally agree” and not relevant in the other 
cases. Regarding the expected rate of success of HFNC 
(i.e., avoiding intubation) according to the different indi-
cations, 6 propositions were possible: “not used in this 
indication”, “1–19%”, “20–39%”, “40–59%”, “60–79%”, “80–
100%”. Responders were categorized as “juniors” for ICU 
physicians with less than 5 years, and “seniors” for those 
with more than 5 years of ICU experience.
Statistics
Demographic data are presented as absolute number 
and median with first and third quartiles. Utilizations 
of HFNC, non-invasive ventilation (NIV) and invasive 
mechanical ventilation for 1000 admissions were cal-
culated. Results concerning HFNC daily practice are 
presented as percentages and proportions of responses. 
Comparisons between the two groups (“juniors” vs “sen-
iors”) were performed using a Fischer’s exact test or a χ2 
test as needed. A p value < 0.05 was considered as statis-




All 34 ICU Medical Heads (from 7 university hospitals, 
26 general hospitals and 1 private hospital) answered the 
demographic data of the survey. HFNC was available and 
regularly used in all ICUs. The median number of phy-
sicians in each medical team was 5.75 [5, 6] ICU physi-
cians and 4 [3–6] residents. The median number of beds 
was 10.5 [8–12] for ICU and 5.5 [4–6.5] for intermedi-
ate care with an ICU physician for 2 [1.7–2.4] beds and a 
nurse for 2.6 [2.5–3] beds. During the year 2015, 17,134 
patients were admitted to the 34 ICUs of the BoReal net-
work, with a median of 798 [449–966] patients per ICU. 
A total of 10,202 patients were admitted for ARF with a 
median of 214 [189.5–390.3] patients per ICU, represent-
ing 59.5% of all admissions. During 2015, 2839 patients 
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were treated with HFNC (166/1000 admissions), 2971 
with NIV (173/1000) and 6604 with invasive mechanical 
ventilation (385/1000).
Regarding the second part of the survey, among the 
235 ICU physicians contacted, 137 responded, i.e,. a 
response rate of 58.3%, with a median ICU expertise of 9 
[5–18] years and a median HFNC use of 5 [3.5–7] years. 
All regularly used HFNC for ARF management (100%, 
137/137). Of these responders, 20 did not answer to the 
items concerning indications or usual practice of HFNC, 
6 answered less than 50% and 111 more than 50% of the 
items, resulting in a mean completion of the survey of 
80.3% [79.6–81%].
Indications for HFNC
Hypoxemic ARF was considered a relevant indica-
tion for HFNC by 100% of responders, and pneumonia 
(98%) and thoracic trauma (91%) were the preferred eti-
ologies, followed by pulmonary embolism (85%), acute 
respiratory distress syndrome (ARDS) (71%), acute pul-
monary edema (57%) and acute severe asthma (40%) 
(Table  1) 0.30% of responders expected HFNC therapy 
to be successful in avoiding intubation in at least 60% 
of hypoxemic ARF cases (Table  2). In contrast, 33% of 
responders considered hypercapnic ARF a relevant indi-
cation for HFNC. The main hypercapnic ARF etiologies 
were bronchial dilatations (32%), thoracic wall deformity 
(32%), chronic obstructive pulmonary disease (COPD) 
exacerbation (28%) and acute pulmonary edema (25%) 
(Table 1). Only, 2% of responders expected HFNC ther-
apy to be successful in avoiding intubation in at least 60% 
of hypercapnic ARF cases (Table  2), which was signifi-
cantly lower than for hypoxemic ARF (p < 0.0001). Nev-
ertheless, 46% of responders estimated that HFNC had 
a 20–39% rate of success in hypercapnic ARF cases. The 
other potential indications considered for HFNC were 
post-extubation ARF prevention (44%), post-extubation 
ARF treatment (70%), post-operative ARF (76%), ARF for 
“ not to be resuscitated” patients (no intubation) for ethi-
cal reasons (92%), preoxygenation before endotracheal 
intubation (84%), and oxygenation during bronchoscopy 
(92%) (Table 1).
Practice of HFNC
Among patients treated for ARF, 40% of ICU physicians 
estimated that HFNC could be indicated for a minimal 
Table 1 Proportion of  ICU physicians estimating the  different potential indications of  high-flow nasal cannula therapy 
as “good” or “very good”
ARF: Acute respiratory failure; ARDS: Acute respiratory distress syndrome; COPD: chronic obstructive pulmonary disease; ETI: endotracheal intubation. HFNC: high-
flow nasal cannula; ICU: intensive care unit
*Comparisons were performed between junior and senior ICU physicians
Overall, % (n) Seniors, % (n) Juniors, % (n) p*
Hypoxemic ARF 100 (111/111) 100 (68/68) 100 (43/43) 1
  Pneumonia 98 (109/111) 97 (66/68) 100 (43/43) 0.52
  Thoracic trauma 91 (100/110) 90 (60/67) 93 (40/43) 0.74
  Pulmonary embolism 85 (94/110) 87 (58/67) 84 (36/43) 0.78
  ARDS 71 (78/110) 67 (45/67) 77 (33/43) 0.39
  Acute pulmonary edema 57 (63/111) 74 (50/68) 30 (13/43) < 0.0001
  Acute severe asthma 40 (44/109) 45 (30/67) 33 (14/42) 0.32
“Do not intubate” patients 92 (100/109) 90 (60/67) 95 (40/42) 0.48
Per bronchoscopy 92 (97/106) 91 (58/64) 93 (39/42) 1
Preoxygenation before ETI 84 (86/102) 81 (51/63) 90 (35/39) 0.28
Post-operative ARF 76 (80/105) 77 (50/65) 75 (30/40) 0.82
Post-extubation ARF treatment 70 (74/105) 70 (45/64) 71 (29/41) 1
Post-extubation ARF prevention 44 (39/89) 45 (25/56) 42 (14/33) 1
Hypercapnic ARF 33 (27/83) 29 (15/52) 39 (12/31) 0.47
  Bronchial dilatation 32 (35/108) 27 (18/67) 41 (17/41) 0.14
  Thoracic wall deformity 32 (35/111) 30 (19/68) 37 (16/43) 0.40
  COPD exacerbation 28 (31/110) 22 (15/67) 37 (16/43) 0.13
  Acute pulmonary edema 25 (28/111) 31 (21/68) 16 (7/43) 0.12
  Neuromuscular disease 20 (22/111) 19 (13/68) 21 (9/43) 0.81
  Obesity hypoventilation syndrome 19 (21/111) 16 (11/68) 23 (10/43) 0.46
  Acute severe asthma 14 (15/111) 15 (10/68) 12 (5/43) 0.78
  Obstructive sleep apnea syndrome 7 (8/110) 6 (4/67) 9 (4/43) 0.71
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COT gas flow of 6 L/min, 39% for 9 L/min, 12% for 12 L/
min and 9% for 15 L/min (Table  3). Initial settings var-
ied according to ICU physician, with 58% starting HFNC 
with a 100%  FiO2 and a gradual increase in gas flow 
and 28% with an initial gas flow ≥ 50 L/min. Regarding 
modalities for administration, 93% regularly used HFNC 
continuously and 54% regularly used it intermittently 
with NIV.
Criteria for HFNC failure (i.e., need for intubation) 
were homogeneous with 95% of responders retaining the 
absence of correction of hypoxemia, 95% a worsening of 
ARF (increase in respiratory rate, nasal flaring, intercos-
tal indrawing, suprasternal or supraclavicular retraction, 
and/or thoraco-abdominal paradoxical motion), 97% 
the occurrence of respiratory pauses or arrest, 81% the 
occurrence of acidosis, 75% the occurrence of a bronchial 
congestion and 61% circulatory insufficiency.
When respiratory conditions had improved, there was 
little variation in modalities for HFNC weaning among 
ICU physicians. Indeed, 81% declared that  FiO2 should 
be reduced first, 6% that gas flow should be reduced 
first and 13% that both parameters should be reduced 
Table 2 Expected success rates of high-flow nasal cannula 
therapy in the different indications
ARF: Acute respiratory failure
*Comparisons were performed between junior and senior ICU physicians
Overall, % (n) Seniors, % (n) Juniors, % (n) p*
All indications 0.95
 1–19% 5 (5/104) 5 (3/66) 5 (2/38)
 20–39% 35 (36/104) 30 (20/66) 42 (16/38)
 40–59% 41 (43/104) 44 (29/66) 36 (14/38)
 ≥ 60% 19 (20/104) 21 (14/66) 16 (6/38)
Hypoxemic ARF 0.81
 1–19% 6 (7/120) 5 (4/75) 7 (3/45)
 20–39% 23 (28/120) 19 (14/75) 31 (14/45)
 40–59% 41 (49/120) 45 (34/75) 33 (15/45)
 ≥ 60% 30 (36/120) 31 (23/75) 29 (13/45)
Hypercapnic ARF 0.88
 1–19% 35 (16/46) 33 (9/27) 37 (7/19)
 20–39% 46 (21/46) 44 (12/27) 47 (9/19)
 40–59% 17 (8/46) 22 (8/27) 11 (2/19)
 ≥ 60% 2 (1/46) 0 5 (1/19)
Table 3 Practices of high-flow nasal cannula therapy among ICU physicians (initiation, weaning, failure)
ARF: Acute respiratory failure; COT: conventional oxygen therapy; HFNC: high-flow nasal cannula
*Comparisons were performed between junior and senior ICU physicians
Overall, n (%) Seniors, n (%) Juniors, n (%) p*
Minimal COT gas flow justifying a switch 
to HFNC
0.67
 6 L/min 40 (41/102) 38 (24/63) 44 (17/39)
 9 L/min 39 (40/102) 43 (27/63) 33 (13/39)
 12 L/min 12 (12/102) 10 (6/63) 15 (6/39)
 15 L/min 9 (9/102) 10 (6/63) 8 (3/39)
Initial HFNC settings
 FiO2 ≥ 50% 58 (62/106) 53 (35/66) 68 (27/40) 0.16
 Gas flow ≥ 50 L/min 28 (30/106) 33 (22/66) 20 (8/40) 0.18
Criteria for HFNC failure
 Breathing arrest 97 (103/106) 95 (40/42) 98 (63/64) 0.56
 Refractory hypoxemia 95 (104/110) 94 (63/67) 95 (41/43) 1
 Acidosis 81 (89/110) 78 (52/67) 86 (37/43) 0.33
 Worsening of ARF 95 (104/110) 100 (67/67) 86 (37/43) 0.003
 Bronchial congestion 75 (83/110) 82 (55/67) 72 (31/43) 0.24
 Circulatory insufficiency 61 (65/106) 72 (48/67) 44 (17/39) 0.007
 Agitation 95 (105/110) 99 (66/67) 91 (39/43) 0.08
 Consciousness disorders 99 (109/110) 99 (66/67) 100 (43/43) 1
 Other organ dysfunction 65 (71/109) 76 (50/66) 49 (21/43) 0.007
Criteria for HFNC weaning 0.33
 FiO2 < 30% 50 (56/111) 57 (39/68) 40 (17/43)
 Gas flow < 20 L/min 16 (18/111) 9 (6/68) 12 (5/43)
 Both previous criteria 30 (33/111) 25 (17/68) 37 (16/43)
 Other 16 (18/111) 9 (6/68) 12 (5/43)
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simultaneously. In contrast, there was more variation in 
the criteria for definitively stopping HFNC; the main cri-
teria were a  FiO2 below 30% for 50% of ICU physicians, 
a gas flow below 20 L/min for 16% and both criteria for 
30% (Table 3).
Comparison between “senior” and “junior” ICU physicians
No difference was observed between senior and jun-
ior ICU physicians regarding HFNC indications except 
for acute pulmonary edema responsible for hypoxemic 
ARF (Table  1). Indeed, 74% of seniors considered this 
indication of HFNC as relevant versus 30% of juniors 
(p < 0.0001). Moreover, no difference was observed for 
the expected success rates of HFNC in the various clini-
cal situations (Table 2).
Similarly, there was no difference for COT gas flow jus-
tifying a switch to HFNC therapy or for the initial HFNC 
settings (Table  3). On the other hand, differences were 
found for criteria of HFNC failure. If 100% of seniors 
considered that worsening of ARF during HFNC therapy 
required endotracheal intubation, only 86% of juniors did 
(p = 0.003). Circulatory insufficiency was also considered 
as a cause for endotracheal intubation for 72% of seniors 
versus only 44% of juniors (p = 0.007), as well as a new 
organ dysfunction for 76% of seniors versus only 49% of 
juniors (p = 0.007). No difference was observed between 
the two groups for the modalities of HFNC weaning 
(Table 3).
The overall satisfaction of HFNC therapy was esti-
mated as excellent and satisfactory in, respectively, 85% 
(93/110) and 15% (17/100) of responders, with no differ-
ence observed between juniors and seniors (84% (36/43) 
versus 85% (57/67) and 16% (7/43) versus 15% (10/67), 
respectively; p = 1).
Discussion
Our study evaluates the clinical experience and percep-
tion of ICU physicians in their use of HFNC therapy. This 
regional multicenter survey shows that ICU physicians in 
Northwest France use HFNC therapy in their daily prac-
tice in a wide range of indications, but mainly in hypox-
emic ARF. The survey also highlights some differences 
in the practical use of HFNC between senior and junior 
ICU physicians.
Indications for HFNC
Not surprisingly, hypoxemic ARF is considered by all 
ICU physicians in our survey as a good indication for 
HFNC, with pneumonia as preferred etiologies. Indeed 
in the randomized controlled study FLORALI including 
310 patients, more than 80% of the ARF population had 
pneumonia [2], providing a good level of evidence in this 
indication. Interestingly and despite the lack of literature 
evidence, 85% of practitioners believe that HFNC could 
be used in pulmonary embolism. Indeed, only one retro-
spective study reported an improvement in oxygenation 
and respiratory rate in 17 cases of pulmonary embolism 
treated with HFNC [15]. Prospective clinical trials are, 
therefore, still needed to assess the efficiency and safety 
of the device in this situation. From a physiological point 
of view, however, the high flow of oxygen could probably 
be able to counteract the alteration of ventilation–per-
fusion ratios without having a major negative impact on 
right ventricular function. Concerning HFNC in cardio-
genic pulmonary edema, there were no specific clinical 
data supporting its use at the time of the survey, despite 
HFNC can generate low levels of positive inspiratory and 
expiratory pressures [16]. However, the levels generated 
remain much lower than those with NIV. Nevertheless, 
the combination of NIV and HFNC could probably be 
useful in this indication [17]. It was striking to note that 
only 30% of ICU physicians in our study expect HFNC 
treatment to be successful in more than 60% of cases of 
hypoxemic ARF, while the FLORALI study observed an 
actual success rate of 62% [2]. The relatively low rate of 
expected HFNC success in hypoxemic ARF in our sur-
vey could reflect the few evidences regarding the poten-
tial benefit of HFNC in hypoxemic ARF at the date of the 
survey or the fact that some physicians could not have 
been already aware of the results. Indeed, apart from the 
FLORALI study [2], only few observational trials have 
suggested a potential favorable outcome with HFNC sup-
port in hypoxemic ARF, with similar level of HFNC suc-
cess (65%) [18]. Moreover, data have suggested that high 
tidal volumes can be responsible for Volume Induced 
Lung Injuries (VILI) [19], even during NIV therapy [20], 
which in association with an excess in respiratory drive 
in patients with spontaneous breathing could promote 
Patient Self-Induced Lung Injury (P-SILI) in hypoxemic 
ARF [21]. This unexpected increase in lung volume has 
recently been demonstrated with NIV [22] which could 
explain the risk of failure and poor outcome with this 
ventilatory support in hypoxemic ARF [2, 22]. Finally, 
based on the current literature, the physiological ben-
efits of HFNC and the potential risk of P-SILI with NIV, it 
seems reasonable to favor HFNC as the first-line therapy 
in hypoxemic ARF [23].
Regarding hypercapnic ARF, only one-third of physi-
cians in our survey consider this indication as potentially 
relevant. This could reflect the lack of reliable clinical 
evidence in this field. Although the physiological effects 
of HFNC, mainly by decreasing  CO2 re-breathing due 
to the anatomical dead space washout, were demon-
strated to be potentially useful in stable COPD [24] and 
to limit or decrease acute hypercapnia [25], no large ran-
domized prospective clinical study has been performed 
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in hypercapnic ARF as yet. Some case reports have sug-
gested a beneficial effect of HFNC to manage hypercap-
nic ARF in COPD patients unable to tolerate NIV [26]. 
Other recent studies published after our survey suggest 
clinical benefits of HFNC in cases of hypercapnia [27–
29]. Up to now, only one small prospective randomized 
study has compared NIV and HFNC in 88 severe COPD 
exacerbations [29]. However, no difference was reported 
on clinical outcome including 30-day intubation and sur-
vival. The lack of clinically relevant studies could explain, 
therefore, the low success rate expected with HFNC sup-
port in hypercapnic ARF (less than 2% of responders 
expected a success rate of more than 60%). Neverthe-
less, 46% of ICU physicians estimate that the success rate 
could be between 20 and 40%, suggesting this technique 
could be considered as a reliable alternative to NIV in 
intolerant hypercapnic ARF patients or a complementary 
support in most severe situations. Further large clinical 
trials are needed to support this indication. In this con-
text, the results of the French prospective randomized 
multicenter “High-Flow ACRF” trial will be helpful [30].
For other indications, only 44% of physicians in our sur-
vey consider that HFNC is potentially relevant to prevent 
post-extubation ARF. Previous studies have suggested 
some physiological benefits of HFNC during the post-
extubation period [31, 32]. Two multicenter prospective 
randomized trials have demonstrated that HFNC could 
be better than COT [33] and not inferior to NIV [34] to 
prevent reintubation and post-extubation ARF in low- 
and high-risk patients, respectively. Results of the ongo-
ing “High-Wean” trial comparing HFNC alone or with 
NIV in the post-extubation period for high-risk patients 
should give further evidence in this indication [35].
For patients with “do not intubate” instructions, more 
than 90% of ICU physicians in our survey consider that 
HFNC is a useful respiratory support. This application 
was later evaluated as beneficial in a retrospective study 
including 84 patients treated with NIV or HFNC showing 
a similar poor survival rate, but a longer maintenance of 
the ability to speak or eat for patients with HFNC [36]. 
HFNC can, thus, combine respiratory comfort, high sat-
isfaction and potential benefit on outcome with a possi-
ble recovery for these patients that could make HFNC a 
first-line respiratory support in these difficult situations.
More than 80% of ICU physicians in our survey con-
sider that HFNC is useful as a preoxygenation technique 
before endotracheal intubation. Interestingly, data avail-
able at the time of this survey were limited to two stud-
ies. An observational before–after study suggested that 
HFNC can significantly improve preoxygenation and 
reduce severe intubation-related hypoxemia in compari-
son with non-rebreathing facemask [11]. The other, a 
multicenter randomized controlled trial, failed to show 
any difference between these two preoxygenation strat-
egies [8]. Several studies have since been published [10, 
37–39]. None of them has provided unquestionable and 
definite data as to the best strategy to preoxygenate ICU 
patients.
Finally and surprisingly, results of our survey highlight 
that despite the lack of strong evidence-based data in the 
different indications identified as potentially relevant, 
HFNC can be readily and widely accepted and used by 
ICU physicians. This is quite unique in the history of ICU 
techniques and management, and clinicians should be 
careful in poorly studied indications, although the physi-
ological benefit and simplicity of HFNC devices could 
explain the wide interest for this technique [1].
Practical modalities of HFNC use
More than half of the ICU physicians in our survey use a 
high  FiO2 level at HFNC initiation, above 50%. This is in 
accordance with some clinical study protocols that rec-
ommend the use of FiO2 up to 50 or 100% [2, 4]. Surpris-
ingly, only 30% use a high-flow rate (at least 50 L/min) at 
HFNC initiation in contrast with most randomized clini-
cal trials [4, 17, 31, 40]. Indeed, a large part of the physio-
logical benefits lies in the HFNC flow rate applied, which 
can proportionally reduce respiratory work, improve 
oxygenation, compliance and pulmonary aeration, inde-
pendent of  FiO2 [41]. In the same way, more than half of 
the ICU physicians in our study indicate that a low  FiO2 
was the main criterion for HFNC weaning, without con-
sidering the flow rate. For the same reasons mentioned 
above, the HFNC flow rate should be considered in the 
weaning process. To our knowledge, no work has specifi-
cally explored the different modalities of HFNC weaning 
in daily practice.
Comparisons between senior and junior ICU physicians
Very few differences are found between senior and jun-
ior ICU physicians in the practice of HFNC. Seniors are 
more likely to consider HFNC in hypoxemic cardiogenic 
pulmonary edema as compared to juniors without clear 
explanation or evidence-based data for this finding. In 
addition, seniors most often consider a circulatory, res-
piratory or other organ failure as a criterion for HFNC 
failure. These small differences could be due to a greater 
confidence in the technology use for juniors. Indeed, 
HFNC has been widely used in our region during the last 
decade. Thus, most young ICU physicians have known 
this technique since the beginning of their practice, 
increasing probably their confidence in the device.
Strengths and limits
This study focuses on ICU physicians’ expectations and 
their self-reported practice regarding HFNC, beyond 
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any clinical trials. It particularly highlights the discrep-
ancy between the lack of evidence for numerous poten-
tial indications at the time of the survey and the wide use 
of HFNC in clinical practice. Some limitations should 
also be underlined. First, the survey was not designed 
according to the Delphi method. Nevertheless, to limit 
the potential bias related to the methodology, we fol-
lowed the available recommendations for self-adminis-
tered questionnaire [14]. Second, a possible discrepancy 
between physicians’ responses and their actual practices 
cannot be formally excluded. Third, the possibility of 
skipping questions could also lead to bias in data collec-
tion, although it guaranteed a higher response rate. The 
58% response rate could be considered as relatively low, 
but a rate between 50 and 60% is often considered accept-
able and reported in the literature for this type of study 
[42]. Fourth, this survey has been performed more than 
2 years ago and could not represent the current practices 
with HFNC in ICU because of the growing literature in 
this field. In addition, some of the results, notably those 
concerning the indications of HFNC, could reflect the 
lack of knowledge of the ICU physicians rather than con-
flicting results from the literature. Finally, although the 
survey was conducted with the French BoReal research 
network not specifically dedicated to respiratory sup-
port, results may not be representative of ICU physicians’ 
clinical experience and perception with HFNC across the 
France or around the world.
Conclusion
In conclusion, HFNC therapy is used by ICU physi-
cians in the North-west region of France in many situa-
tions of ARF despite limited available evidence in most 
of these indications at the time of the survey. While 
criteria for HFNC failure were found homogeneous, 
there were some discrepancies between ICU physicians 
regarding the strategies and criteria for HFNC wean-
ing. Despite the physiological benefit and simplicity of 
HFNC technique, further prospective studies on clini-
cal practices and relevant outcomes with HFNC are 
still warranted.
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